908 Devices (NASDAQ:MASS – Free Report) had its price target trimmed by Leerink Partners from $15.00 to $12.00 in a research note published on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.
908 Devices Stock Up 4.7 %
Shares of NASDAQ MASS opened at $3.59 on Thursday. The company has a market capitalization of $123.80 million, a PE ratio of -3.36 and a beta of 0.97. 908 Devices has a twelve month low of $3.24 and a twelve month high of $12.51. The firm has a fifty day simple moving average of $3.73 and a 200 day simple moving average of $5.02.
908 Devices (NASDAQ:MASS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.02. The firm had revenue of $14.05 million during the quarter, compared to analyst estimates of $13.69 million. 908 Devices had a negative return on equity of 22.47% and a negative net margin of 72.10%. As a group, equities analysts expect that 908 Devices will post -1.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On 908 Devices
About 908 Devices
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Recommended Stories
- Five stocks we like better than 908 Devices
- How is Compound Interest Calculated?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Calculate Return on Investment (ROI)
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.